Florent Puisset

812 total citations
35 papers, 521 citations indexed

About

Florent Puisset is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Florent Puisset has authored 35 papers receiving a total of 521 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Pharmacology. Recurrent topics in Florent Puisset's work include Cancer Treatment and Pharmacology (7 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Florent Puisset is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Florent Puisset collaborates with scholars based in France, Netherlands and United States. Florent Puisset's co-authors include Étienne Chatelut, Mélanie White‐Koning, Cécile Arellano, Thierry Lafont, Alex Sparreboom, Ron H.J. Mathijssen, Sharyn D. Baker, Christine Chevreau, Florence Dalenc and Vania Bernardes‐Génisson and has published in prestigious journals such as Journal of Medicinal Chemistry, British Journal of Cancer and Clinical Pharmacology & Therapeutics.

In The Last Decade

Florent Puisset

33 papers receiving 510 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Florent Puisset France 13 215 113 106 100 61 35 521
Nathalie Letarte Canada 10 221 1.0× 141 1.2× 137 1.3× 68 0.7× 33 0.5× 26 477
Elena Guerini Switzerland 15 208 1.0× 222 2.0× 191 1.8× 81 0.8× 35 0.6× 29 793
Anshu Marathe United States 11 203 0.9× 112 1.0× 183 1.7× 46 0.5× 49 0.8× 22 559
Jean-Christophe Boyer France 14 219 1.0× 82 0.7× 136 1.3× 86 0.9× 67 1.1× 35 634
Stéphanie van Hoppe Netherlands 12 257 1.2× 73 0.6× 148 1.4× 45 0.5× 42 0.7× 15 449
J. Alexandre France 15 370 1.7× 205 1.8× 170 1.6× 61 0.6× 55 0.9× 45 755
Daiki Tsuji Japan 14 159 0.7× 51 0.5× 137 1.3× 61 0.6× 36 0.6× 50 568
Suman Lal Singapore 14 264 1.2× 58 0.5× 186 1.8× 157 1.6× 33 0.5× 26 859
Devron R. Shah United Kingdom 7 241 1.1× 187 1.7× 190 1.8× 77 0.8× 41 0.7× 8 599
Emiko Sugiyama Japan 15 395 1.8× 125 1.1× 257 2.4× 210 2.1× 110 1.8× 32 1.0k

Countries citing papers authored by Florent Puisset

Since Specialization
Citations

This map shows the geographic impact of Florent Puisset's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florent Puisset with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florent Puisset more than expected).

Fields of papers citing papers by Florent Puisset

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florent Puisset. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florent Puisset. The network helps show where Florent Puisset may publish in the future.

Co-authorship network of co-authors of Florent Puisset

This figure shows the co-authorship network connecting the top 25 collaborators of Florent Puisset. A scholar is included among the top collaborators of Florent Puisset based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florent Puisset. Florent Puisset is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ranchon, Florence, Florian Slimano, Isabelle Borget, et al.. (2025). Oncology pharmacy practice: Key insights, challenges, and perspectives – A position paper from the French Society for Oncology Pharmacy (SFPO). Annales Pharmaceutiques Françaises. 83(6). 1040–1052.
2.
Fillaudeau, Luc, et al.. (2024). A comparative study of gellan gum and xanthan gum versus commercial vehicles as pharmaceutical thickening agents in oral suspensions. European Journal of Pharmaceutics and Biopharmaceutics. 207. 114622–114622. 1 indexed citations
3.
Puisset, Florent, Loı̈c Mourey, Damien Pouessel, et al.. (2023). Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer. Cancers. 15(1). 313–313. 5 indexed citations
4.
Lafaurie, Margaux, Emmanuel Treiner, Ondine Walter, et al.. (2023). Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases. International Immunopharmacology. 120. 110342–110342. 3 indexed citations
5.
6.
Puisset, Florent, Florence Dalenc, Marion Montastruc, et al.. (2023). Investigating the clinical impact of dose‐banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study. British Journal of Clinical Pharmacology. 89(7). 2283–2294.
7.
Puisset, Florent, et al.. (2021). Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr. CPT Pharmacometrics & Systems Pharmacology. 10(10). 1208–1220. 24 indexed citations
8.
9.
Thomas, Fabienne, Mélanie White‐Koning, Ben Allal, et al.. (2021). Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data. Pharmaceuticals. 14(2). 162–162. 4 indexed citations
10.
Lefèbvre, Caroline, E. Martin, Lizza Hendriks, et al.. (2020). Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. Respiratory Medicine and Research. 78. 100788–100788. 7 indexed citations
11.
White‐Koning, Mélanie, et al.. (2020). Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance. Cancer Chemotherapy and Pharmacology. 85(3). 585–592. 13 indexed citations
12.
Lefèbvre, Caroline, E. Martin, Lizza Hendriks, et al.. (2019). P1.01-120 Immune Checkpoint Inhibitors Versus Second Line Chemotherapy for Patients with Lung Cancer Refractory to First Line Chemotherapy. Journal of Thoracic Oncology. 14(10). S409–S409. 1 indexed citations
13.
Puisset, Florent, et al.. (2018). Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit. Supportive Care in Cancer. 27(5). 1679–1686. 5 indexed citations
14.
Puisset, Florent, et al.. (2018). Simultaneous monitoring of pazopanib and its metabolites by UPLC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 154. 373–383. 12 indexed citations
15.
Chatelut, Étienne & Florent Puisset. (2014). The Scientific Basis of Body Surface Area–Based Dosing. Clinical Pharmacology & Therapeutics. 95(4). 359–361. 22 indexed citations
16.
Chatelut, Étienne, Mélanie White‐Koning, Ron H.J. Mathijssen, et al.. (2012). Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. British Journal of Cancer. 107(7). 1100–1106. 68 indexed citations
17.
Puisset, Florent, J. Alexandre, Jean‐Marc Tréluyer, et al.. (2007). Clinical pharmacodynamic factors in docetaxel toxicity. British Journal of Cancer. 97(3). 290–296. 29 indexed citations
18.
Puisset, Florent, Étienne Chatelut, Alex Sparreboom, et al.. (2006). Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect. Cancer Chemotherapy and Pharmacology. 60(2). 305–308. 11 indexed citations
19.
Puisset, Florent, Florence Dalenc, Étienne Chatelut, et al.. (2005). Dexamethasone as a probe for vinorelbine clearance. British Journal of Clinical Pharmacology. 60(1). 45–53. 12 indexed citations
20.
Puisset, Florent, Étienne Chatelut, Florence Dalenc, et al.. (2004). Dexamethasone as a probe for docetaxel clearance. Cancer Chemotherapy and Pharmacology. 54(3). 265–72. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nathalie Letarte Breakdown of academic impact, for papers by Elena Guerini Breakdown of academic impact, for papers by Anshu Marathe Breakdown of academic impact, for papers by Jean-Christophe Boyer Breakdown of academic impact, for papers by Stéphanie van Hoppe Breakdown of academic impact, for papers by J. Alexandre Breakdown of academic impact, for papers by Daiki Tsuji Breakdown of academic impact, for papers by Suman Lal Breakdown of academic impact, for papers by Devron R. Shah Breakdown of academic impact, for papers by Emiko Sugiyama
Rankless by CCL
2026